NIKKEI 225
38,236.07 -37.98 (-0.10%) HANG SENG
18,413.79 +206.66 (+1.14%) CRUDE OIL
79.22 +0.27 (+0.34%) GOLD FUTURES
2,312.30 +2.70 (+0.12%) DOW
38,225.66 +322.37 (+0.85%) Bitcoin GBP
47,655.38 +1,936.08 (+4.23%)
ABUS Sep 2024 5.000 call
| Previous close | 0.0600 |
| Open | 0.1000 |
| Bid | 0.0000 |
| Ask | 2.9500 |
| Strike | 5.00 |
| Expiry date | 2024-09-20 |
| Day's range | 0.1000 - 0.1000 |
| Contract range | N/A |
| Volume | |
| Open interest | 675 |
- GuruFocus.com
Arbutus Biopharma Corp Reports Q1 2024 Earnings: A Detailed Financial Review
Insights into Arbutus Biopharma's First Quarter Performance and Strategic Updates
ZacksArbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates
Arbutus (ABUS) delivered earnings and revenue surprises of 0% and 28.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireArbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
End-of-treatment data from two Phase 2a combination clinical trials with imdusiran to be presented at the EASL Congress in June 2024 Preliminary data from the single-dose portion of the AB-101-001 clinical trial show that AB-101 was generally well-tolerated and bound to the receptor target in healthy subjects Court provides claim construction ruling in ongoing patent infringement lawsuit against Moderna; Court date scheduled for April 21, 2025 Strong financial position – expected cash runway ext
